auranofin
- Coral Way Pharma
-
3 mgcapsule
-
85437-093-0611-digit: 85437-0093-0660 capsules per bottle
-
Source: FDA, updated October 30, 2026
Generic name: auranofin
Used for: Rheumatoid arthritis
Ask for the cash price
Authorized generic
Ridaura itself, without the brand name. It usually costs less than Ridaura.
None is sold. The authorized generic is the only generic.
Details for each option
We didn’t find a savings card or cash price from Ridaura’s maker. Ask the pharmacy for Ridaura’s cash price. With insurance, ask what your plan charges.
The same medicine as Ridaura, without the brand name. Give the pharmacy its NDC to get it.
auranofin
Source: FDA, updated October 30, 2026
“Before you fill my Ridaura, can you tell me what I’d pay for the brand, for the authorized generic from Coral Way Pharma (NDC 85437-093-06)?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Official labels and ingredient lists from DailyMed (U.S. National Library of Medicine).
Same active and inactive ingredients as Ridaura.
Active: auranofin 3 mg
Inactive, on both labels:
None is sold. The authorized generic is the only generic. Generics usually come once the brand’s patents and exclusivity end. Until then, the authorized generic is the lower-cost way to get Ridaura.
RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies.
Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months.
When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage.
In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy.
Source: the FDA label for Ridaura (Sebela Pharmaceuticals Inc.), November 8, 2025. Full label on DailyMed
Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/ridaura/